Eli Lilly (LLY) Alzheimer's Drug Donanemab Gets FDA Panel Nod

An FDA committee assessing the safety and effectiveness of Eli Lilly and Company’s (LLY) Alzheimer's disease drug, donanemab, voted 11-0, thus unanimously recommending its approval.The Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) said that data from clinical studies supported the efficacy of donanemab for early symptomatic Alzheimer’s patients. The committee said the studies demonstrated substantial evidence of efficacy and clinically meaningful slowing of disease progression that w ...